Perforation

Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI®

Retrieved on: 
Wednesday, November 30, 2022
United, Liver, Kidney, United States Patent and Trademark Office, Risk, Bronchospasm, Creatinine, Tardive dyskinesia, Hyperprolactinaemia, Hypertension, NMS, Metoclopramide, Hypersensitivity, Dysgeusia, Patient, Suicidal ideation, Fatigue, Neoplasm, EPS, Catecholamine, TD, Seizure, Gastroparesis, FDA, Internal bleeding, COVID-19, Epilepsy, Suicide, Evoke, History, Parkinsonism, CYP2D6, Methemoglobinemia, Extrapyramidal symptoms, Vomiting, Patent, Depression, Physiology, Water, Stomach, Perforation, Headache, Neuroleptic malignant syndrome, Absorption, Pheochromocytoma, Pharmaceutical industry, Aroma compound, Residential care, Generic drug

This patent application is a continuation of several other U.S. patent applications filed by the company over the last decade.

Key Points: 
  • This patent application is a continuation of several other U.S. patent applications filed by the company over the last decade.
  • We are thrilled and highly encouraged by the strides we have made with the USPTO and its continued acknowledgement of the novel and inventive nature of GIMOTI, said Matt DOnofrio, Chief Business Officer of Evoke Pharma.
  • Most common adverse reactions (5%) for GIMOTI are: dysgeusia, headache, and fatigue.These are not all of the possible side effects of GIMOTI.
  • Call your doctor for medical advice about whether you should take GIMOTI and the possible risk factors and side effects.

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Retrieved on: 
Monday, November 28, 2022
Marketing, COVID-19, Perforation, Biologically based mental illness, Incidence, Severe cognitive impairment, Mouth ulcer, Food, Hand, IND, Safety, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MSC, Disease, Neurotrophic keratitis, Protease, Security (finance), IgG4-related ophthalmic disease, Scar, Research, Coronavirus, Biologics license application, KALA, Eye, Infection, FDA, BLA, Pharmaceutical industry

ARLINGTON, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced the submission of an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for KPI-012 for the treatment of Persistent Corneal Epithelial Defect (PCED). Subject to acceptance of the IND by the FDA, Kala remains on-track to initiate a Phase 2b clinical trial of KPI-012 for PCED in the fourth quarter of 2022. Topline safety and efficacy data from the trial is expected in the first quarter of 2024. If positive, this trial could serve as the first of two pivotal trials needed to support the submission of a Biologics License Agreement (BLA) to the FDA. Following acceptance of the IND for KPI-012 by the FDA, Kala will receive the second tranche from the private placement of securities announced earlier today which, together with current cash on hand, Kala expects will extend its projected cash runway into the first quarter of 2025.

Key Points: 
  • Topline safety and efficacy data from the trial is expected in the first quarter of 2024.
  • If positive, this trial could serve as the first of two pivotal trials needed to support the submission of a Biologics License Agreement (BLA) to the FDA.
  • Persistent corneal epithelial defect, which is defined as a persistent non-healing corneal defect or wound that is refractory to conventional treatments, is a rare disease with an estimated incidence in the United States of 100,000 cases per year.
  • KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received orphan drug designation from the U.S. Food and Drug Administration.

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Retrieved on: 
Monday, November 28, 2022
Marketing, COVID-19, Perforation, United, Biologically based mental illness, Incidence, Severe cognitive impairment, Mouth ulcer, Food, IND, Safety, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Disease, Neurotrophic keratitis, Protease, Security (finance), Scar, Sale, Research, Biologics license application, Coronavirus, KALA, Eye, Infection, FDA, BLA, Pharmaceutical industry

Kala intends to use proceeds from the financing to advance the clinical development of KPI-012 for the treatment of PCED, as well as for general corporate purposes.

Key Points: 
  • Kala intends to use proceeds from the financing to advance the clinical development of KPI-012 for the treatment of PCED, as well as for general corporate purposes.
  • Kala is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye.
  • This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties.
  • Kala does not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Kerr Dental Releases ZenFlexTM ONE Reciprocating File for Efficient and Cost-Effective Endodontic Procedures

Retrieved on: 
Wednesday, November 23, 2022
Kerr, Marketing, Risk, Perforation, Transport, Health insurance

BREA, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Kerr Dental announces the launch of its novel ZenFlex ONE reciprocating file featuring a counter-clockwise flute.

Key Points: 
  • BREA, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Kerr Dental announces the launch of its novel ZenFlex ONE reciprocating file featuring a counter-clockwise flute.
  • The new ZenFlex ONE file, alongside its matching Gutta Percha and Paper Points, offers a simple solution for endodontic specialists and general practitioners performing root canal procedures.
  • "The result is a high-performing reciprocating file that practitioners can rely on when performing procedures for a wide range of anatomies."
  • With ZenFlex ONE, doctors now have an affordable, reliable, and durable reciprocating file that increases efficiency without the need to change technique.

TRILLION ENERGY ANNOUNCES FLOW TEST RESULTS FOR AKCAKOCA-3 WELL

Retrieved on: 
Monday, November 21, 2022
Well, Perforation, Vranino, Sand, Cendere, Nallıhan, Natural gas, Black, CSE, Oil

, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Trillion Energy International Inc. (Trillion or the Company) (CSE: TCF) (OTCQB: TRLEF) (Frankfurt: Z62) is pleased to announce flow test results for the Akcakoca-3 natural gas well at the SASB gas field, offshore Turkey.

Key Points: 
  • , Nov. 21, 2022 (GLOBE NEWSWIRE) -- Trillion Energy International Inc. (Trillion or the Company) (CSE: TCF) (OTCQB: TRLEF) (Frankfurt: Z62) is pleased to announce flow test results for the Akcakoca-3 natural gas well at the SASB gas field, offshore Turkey.
  • Three sands with a total of 34 metres of natural gas pay were identified for perforation in the Akcakoca-3 well.
  • Arthur Halleran CEO of Trillion stated:
    We are very pleased that our multi-well drilling program is off to a very strong start.
  • Trillion Energy is focused on natural gas production for Europe and Trkiye with natural gas assets in Trkiye and Bulgaria.

FDA Approves Medicines360's LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Eight Years

Retrieved on: 
Monday, November 14, 2022
SAN, Polyethylene, Internal bleeding, Endometritis, Body mass index, ACCESS, IUS, Pain, Infertility, Levonorgestrel, IUD, Population, PID, Woman, Obstetrics, Faecal calprotectin, Infection, Uterus, American Journal of Obstetrics and Gynecology, Abdominal pain, Risk, Safety, Sores, FDA, Pregnancy, Gynaecology, Ectopic pregnancy, Medicine, Fibroid, Department, HIV, Time, Barium sulfate, Birth certificate, University of Pennsylvania Health System, Vaginal bleeding, Multimedia, American Journal, Pelvic inflammatory disease, Hysterectomy, Death, Patient, Chills, Pelvic pain, Policy, Condom, CEO, BMI, Sex, STD, Allergy, Professor, AbbVie, Review, Perforation, Fever, Food, Shanda, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Birth control, Dietary supplement, Pharmaceutical industry

SAN FRANCISCO, Nov. 14, 2022 /PRNewswire/ -- Medicines360, a global nonprofit organization with a mission to expand women's access to quality medicines, announced today that the U.S. Food and Drug Administration (FDA) has approved Medicines360's Supplemental New Drug Application (sNDA) to extend the duration of use of Liletta® (levonorgestrel-releasing intrauterine system) 52 mg to prevent pregnancy for up to eight years. This approval is based on data from ACCESS IUS (A Comprehensive Contraceptive Efficacy & Safety Study of an IUS) that Medicines360 first published in the American Journal of Obstetrics and Gynecology in May 2022. With this FDA approval, LILETTA has one of the longest approved durations of use for a hormonal intrauterine device (IUD or IUS) in the U.S.

Key Points: 
  • LILETTA was approximately 99% effective in preventing pregnancy for up to eight years in a diverse population of women.
  • LILETTA is a hormone-releasing system placed in the uterus to prevent pregnancy for up to eight years.
  • LILETTA (levonorgestrel-releasing intrauterine system) 52mg is a hormone-releasing system placed in your uterus to prevent pregnancy for as long as you want for up to 8 years.
  • If you get pregnant while using LILETTA, you may have an ectopic pregnancy, which means the pregnancy is not in the uterus.

UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, November 10, 2022
Medical Devices, Medical Supplies, Hospitals, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Oncology, Adult, Clothing, Risk, Transitional epithelium, Patient Information Advisory Group, Stomach, Company, Pharmakon—Danish College of Pharmacy Practice, Kidney, Recurrence, Blood, Ureter, Swelling, Birth, Urination, Urinary tract infection, SEC, NMIBC, Water, Time, Cancer, Orphan drug, Neoplasm, Patient, UTUC, Urine, COVID-19, Vomiting, Private Securities Litigation Reform Act, Sodium bicarbonate, Bone marrow, Medicine, Clinical trial, Breast milk, Fatigue, Skin, Growth, Abdomen, Nausea, Perforation, NDA, FDA, Trial of the century, Urinary bladder, Fever, Technology, View, Man, Safety, Female, Pain, Transitional cell carcinoma, Nephrectomy, Pharmaceutical industry, Medical imaging, Health insurance, Birth control, Tanning (leather), Phosphorus, Generic drug, Mitomycins, Mitomycin C

The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.

Key Points: 
  • The U.S. FDA previously granted Orphan Drug, Fast Track, and Breakthrough Therapy Designations to Jelmyto for the treatment of LG-UTUC.
  • You should not receive JELMYTO if you have a hole or tear (perforation) of your bladder or upper urinary tract.
  • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with JELMYTO.
  • JELMYTO and UroGen are registered trademarks of UroGen Pharma Ltd.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005284/en/

Helicoid Industries Inc. is proud to announce it has successfully released three use cases of its performance enhancing technology

Retrieved on: 
Wednesday, November 9, 2022
Carbon, National university, NCF, Technology, Industry, Engineering, EV, Transport, Electric vehicle, National University of Singapore, Perforation, CA, Columbia Pictures Industries, Inc. v. Fung, Flax, Conference, Pearson Yachts, Traffic engineering (transportation), Efficiency, Solution, Economic and Technology Co-operation Agreement, UD, Failure, Fireworks, 3D printing, Carbon fibers, Saerbeck, Operation, Helicoid, Airborne

INDIO, Calif., Nov. 9, 2022 /PRNewswire-PRWeb/ --The bio inspired Helicoid™ technology enables improved performance of advanced composites, leading to lighter structures, while achieving excellent cost efficiency and sustainability. The deployment of Helicoid™ technology can be realized with no change in raw materials (fiber and resin), and no change in the manufacturing process. Therefore, the benefits are achieved with no supply chain disruption. The first use case was a collaboration between Helicoid Industries Inc., TPI Composites, Inc. and SAERTEX GmbH (Saerbeck, Germany) focusing on improving the mechanical performance of Electric Vehicle (EV) battery pack underbody protection plates made of innovative E-glass Helicoid™ multiaxial non-crimp fabrics infused with a thermoset resin.

Key Points: 
  • The deployment of Helicoid technology can be realized with no change in raw materials (fiber and resin), and no change in the manufacturing process.
  • In a collaboration with National University of Singapore, Helicoid Industries has demonstrated that the Helicoid technology can be successfully tailored to enhance impact performance of a wide set of natural fiber composites and their hybrids.
  • Helicoid Industries is a California based company founded in 2019 by a seasoned team of experts working to commercialize the Helicoid biomimetic fiber-reinforced composite technology.
  • Helicoid Industries both licenses the technology to composite producers, as well as produces preform solutions.

APAC Polypropylene based Nonwoven Geotextile Market Report 2022: Rise in Demand from the Construction Industry Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, November 7, 2022
Manufacturing, Textiles, Other Construction & Property, Construction & Property, Chemicals, Plastics, Forecast, Growth, Lake, Soil, CAGR, Competition, Rapidan Dam Canal of the Rappahannock Navigation, APAC, Pi bond, Perforation, Government, Construction, Road, GSM, Carpet, Technology, Thermal

The market is driven by the factors such as the rise in demand from the construction industry and the increase in the consumption of bio-based geotextiles.

Key Points: 
  • The market is driven by the factors such as the rise in demand from the construction industry and the increase in the consumption of bio-based geotextiles.
  • The Asia-Pacific Polypropylene Based Non-Woven Geotextile Market is segmented into technology, end-use, GSM, company, and regional distribution.
  • The high demand for the polypropylene based non-woven geotextiles in the construction industry is driving the market demand.
  • In this report, the Asia-Pacific Polypropylene Based Non-woven Geotextile Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
    APAC Polypropylene Based Non-Woven Geotextile Market, By Technology:

Permex Petroleum Successfully Completes Drilling Phase of its First Breedlove Oilfield Well

Retrieved on: 
Wednesday, November 2, 2022
Permian, Growth, CEO, News, CSE, GLOBE, FSE, Company, Production, Perforation, Breedlove, Oil

On September 28th, Permex announced that drilling had commenced and that the well spudded on Wednesday, September 14, 2022.

Key Points: 
  • On September 28th, Permex announced that drilling had commenced and that the well spudded on Wednesday, September 14, 2022.
  • It is the first well drilled by Permex on the 7,780 gross acre Breedlove Oilfield.
  • In addition, Permex plans to further expand into the Eoff PPC #3 wells 40-acre spacing available to create additional drilling programs.
  • The focus of our drilling campaign has been on the Eoff PPC #3 well, which we believe to be the start of a successful drilling campaign on the Breedlove oilfield.